SPRO stock holds its ground on Spero Therapeutics financing and pipeline

Spero Therapeutics (US85208T1079) remains a small-cap Nasdaq name that investors still value through capital structure, cash runway, and pipeline execution. Its latest available public materials show $20.0 million of cash and cash equivalents at 31 March 2026, $112.3 million of revenue in fiscal 2025, and $77.6 million of research and development expense in fiscal 2025.

Cash and revenue still matter

The most recent annual report showed fiscal 2025 revenue of $112.3 million, while research and development expense reached $77.6 million in the same year. That mix leaves the business model easy to read for investors: revenue is still large enough to matter, but development spending also remains a central drain on earnings power.

At 31 March 2026, the company reported $20.0 million in cash and cash equivalents. For a development-stage biotech, that figure matters as much as the pipeline, because it frames how much flexibility management has before the next funding decision becomes unavoidable.

Fiscal 2025 numbers frame the story

The fiscal 2025 filing also showed general and administrative expense of $35.2 million and net loss of $40.1 million. Those figures underline a year in which overhead stayed elevated even as the company continued to fund clinical and commercial priorities.

Compared with fiscal 2024, revenue of $112.3 million was lower than the prior year's $134.6 million, while the net loss widened from $27.4 million to $40.1 million. That year-over-year change is the clearest quantified comparison in the latest public numbers and it explains why balance-sheet scrutiny remains high.

Nasdaq still sets the tone

Spero Therapeutics trades on Nasdaq, which keeps market attention on the shares even when the operating news flow is limited. The stock has a market value that is still driven less by scale than by the probability that the company can extend its financial runway and protect the value of its product platform.

The company’s latest filing showed total assets of $57.1 million and total liabilities of $52.2 million at 31 March 2026. With those numbers close together, any additional financing, licensing, or commercialization update can matter more for valuation than a small change in quarterly revenue.

Product focus stays narrow

The company was built around antibacterial and infectious-disease assets, and that product mix remains central to the investment case. Investors still track progress around the lead franchise because the latest revenue and expense numbers show that Spero is not yet in a phase where scale alone can absorb operating costs.

Revenue of $112.3 million in fiscal 2025, R&D expense of $77.6 million, and a net loss of $40.1 million together show a company still balancing commercialization with ongoing investment. That combination makes product execution and balance-sheet discipline the two variables that matter most.

Price near the latest close

Spero Therapeutics shares last closed at $0.00 on 20 July 2026 in the available market snapshot. The same snapshot was not accompanied by a verified current-session quote in the source set, so the article stays anchored to the dated operating and balance-sheet figures above.